Get started
Author

Mohamed H. Zaki

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
2013 · Jesus San Miguel, Katja Weisel, et al. · The Lancet Oncology · 801
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
2019 · Paul G Richardson, Albert Oriol, et al. · The Lancet Oncology · 384
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
2014 · Paul G. Richardson, David S. Siegel, et al. · Blood · 381
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
2016 · Meletios A. Dimopoulos, Antonio Palumbo, et al. · Blood · 165
PDF
Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice
2006 · Lauren Wallner, Jinlu Dai, et al. · Cancer Research · 144
PDF
Chlamydia pneumoniae Inhibits Apoptosis in Human Peripheral Blood Mononuclear Cells Through Induction of IL-10
2000 · Yuemei Geng, Ryan B Shane, et al. · The Journal of Immunology · 130
CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice
2004 · Mohamed H. Zaki, Jeffrey A. Nemeth, et al. · International Journal of Cancer · 117
Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma
2007 · Peter M. Voorhees, Qing Chen, et al. · Clinical Cancer Research · 115
PDF
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1
2006 · I T Cavarretta, H Neuwirt, et al. · Oncogene · 103
Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines
2002 · Maria Wysocka, Mohamed H. Zaki, et al. · Blood · 75
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
2015 · M. A. Dimopoulos, K. C. Weisel, et al. · Haematologica · 72
PDF
The Role for Interleukin‐12 Therapy of Cutaneous T Cell Lymphoma
2001 · ALAIN H. ROOK, MOHAMED H. ZAKI, et al. · Annals of the New York Academy of Sciences · 56
Cutaneous castleman's disease responds to anti–interleukin-6 treatment
2007 · Bilal Ahmed, Jaime A. Tschen, et al. · Molecular Cancer Therapeutics · 55
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
2015 · J. F. San Miguel, K. C. Weisel, et al. · Haematologica · 52
PDF
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
2015 · Katja Weisel, Meletios Dimopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia · 45
Mcl-1 is Regulated by IL-6 and Mediates the Survival Activity of the Cytokine in a Model of Late Stage Prostate Carcinoma
2008 · Ilaria Teresa Cavarretta, Hannes Neuwirt, et al. · Advances in experimental medicine and biology · 41
Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328
2006 · Hannes Steiner, Ilaria T. Cavarretta, et al. · The Prostate · 39
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
2017 · P G Richardson, C C Hofmeister, et al. · Leukemia · 37
PDF
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
2016 · David S. Siegel, Katja C. Weisel, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 36
PDF
Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study
2012 · Meletios A. Dimopoulos, Martha Q Lacy, et al. · Blood · 35
Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results
2011 · Paul G. Richardson, David S. Siegel, et al. · Blood · 34
Disruption of the IFN-γ cytokine network in chronic lymphocytic leukemia contributes to resistance of leukemic B cells to apoptosis
2000 · Mohamed Zaki, Raymond Douglas, et al. · Leukemia Research · 33
Synergistic Enhancement of Cell-Mediated Immunity by Interleukin-12 Plus Interleukin-2: Basis for Therapy of Cutaneous T Cell Lymphoma
2002 · Mohamed H. Zaki, Maria Wysocka, et al. · Journal of Investigative Dermatology · 28
PDF
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis
2017 · Philippe Moreau, Meletios A. Dimopoulos, et al. · European Journal Of Haematology · 24
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
2014 · K. W. Song, M. A. Dimopoulos, et al. · Haematologica · 24
PDF
Works count: 105
Citation count: 3,471
H-index: 24
I10-index: 46
Year
Topic
Type